Plancorp LLC boosted its position in Allergan PLC. (NYSE:AGN) by 1.0% during the second quarter, Holdings Channel reports. The firm owned 2,582 shares of the company’s stock after buying an additional 26 shares during the period. Plancorp LLC’s holdings in Allergan PLC. were worth $628,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Feltz Wealth PLAN Inc. purchased a new position in Allergan PLC. during the first quarter worth approximately $107,000. Nisa Investment Advisors LLC increased its position in Allergan PLC. by 12.9% in the first quarter. Nisa Investment Advisors LLC now owns 95,746 shares of the company’s stock worth $22,876,000 after buying an additional 10,903 shares during the period. Bank of The West increased its position in Allergan PLC. by 11.5% in the first quarter. Bank of The West now owns 19,937 shares of the company’s stock worth $4,763,000 after buying an additional 2,054 shares during the period. Capital Investment Advisors LLC increased its position in Allergan PLC. by 1.0% in the first quarter. Capital Investment Advisors LLC now owns 6,342 shares of the company’s stock worth $1,515,000 after buying an additional 60 shares during the period. Finally, Benson Investment Management Company Inc. increased its position in Allergan PLC. by 1.3% in the first quarter. Benson Investment Management Company Inc. now owns 8,779 shares of the company’s stock worth $2,097,000 after buying an additional 110 shares during the period. Institutional investors own 83.63% of the company’s stock.
Shares of Allergan PLC. (AGN) traded down 0.93% during mid-day trading on Thursday, hitting $225.86. The company had a trading volume of 1,364,567 shares. The firm’s 50 day moving average is $244.51 and its 200-day moving average is $238.70. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The firm has a market cap of $75.51 billion, a PE ratio of 6.88 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the business posted $3.35 earnings per share. On average, equities analysts expect that Allergan PLC. will post $16.27 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.23%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
A number of equities analysts have recently commented on the company. Mizuho restated a “buy” rating and issued a $267.00 price objective on shares of Allergan PLC. in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 target price on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Company raised their target price on Allergan PLC. to $278.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG reiterated a “buy” rating and set a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, Vetr upgraded Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a report on Monday, June 26th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.